Single dose streptozotocin-induced diabetes: Considerations for study design in islet transplantation models

Laboratory Animals

Volumn 45, Issue 3, 2011, Pages 131-140

  Deeds, M C ^a   Anderson, J M ^a   Armstrong, A S ^a   Gastineau, D A ^a   Hiddinga, H J ^b   Jahangir, A ^a   Eberhardt, N L ^b,c   Kudva, Y C ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Diabetes mellitus; Islet transplantation; Mortality; Refinement; Streptozotocin

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; STREPTOZOCIN;

CIRCADIAN RHYTHM; DIET; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG SOLUTION; DRUG STORAGE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LOW DRUG DOSE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FEMALE; MALE; METHODOLOGY; MOUSE; NUDE MOUSE; PANCREAS ISLET; PATHOPHYSIOLOGY;

ANIMALIA; MUS MUSCULUS; RODENTIA;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, NUDE; RESEARCH DESIGN; SEX FACTORS; STREPTOZOCIN;

EID: 80054695683     PISSN: 00236772     EISSN: None     Source Type: Journal    
DOI: 10.1258/la.2010.010090     Document Type: Review

References (54)

1. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 2005;7:307-17
2. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Ind J Med Res 2007;125:451-72
3. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med 2005;22:359-70
4. Cheta D. Animal models of type I (insulin-dependent) diabetes mellitus. J Pediatr Endocrinol Metab 1998;11:11-19
5. McNeill JH. Experimental Models of Diabetes. Boca Raton: CRC Press LLC, 1999
6. Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963;29:91-8
7. Boven E, Winograd B. The Nude Mouse in Oncology Research. Boca Raton: CRC Press, 1991
8. Beattie G, Lannom R, Lipsick J, Kaplan NO, Osler AG. Streptozotocin-induced diabetes in athymic and conventional BALB/c mice. Diabetes 1980;29:146-50
9. Ricordi C, Kneteman NM, Scharp DW, Lacy PE. Transplantation of cryopreserved human pancreatic islets into diabetic nude mice. World J Surg 1988;12:861-5
10. Nakamura M, Nagafuchi S, Yamaguchi K, Takaki R. The role of thymic immunity and insulitis in the development of streptozocin-induced diabetes in mice. Diabetes 1984;33:894-900
11. Nakano M, Matsumoto I, Sawada T, et al. Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas 2004;29:104-9
12. Zanozar [package insert]. Irvine, CA: Teva Parenteral Medicines, Inc, May 1993
13. Karunanayake EH, Hearse DJ, Mellows G. The synthesis of [14C] streptozotocin and its distribution and excretion in the rat. Biochem J 1974;142:673-83
14. Povoski SP, McCullough PJ, Zhou W, Bell RH Jr. Induction of diabetes mellitus in Syrian golden hamsters using stored equilibrium solutions of streptozotocin. Lab Anim Sci 1993;43:310-14
15. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res/Acad Scientiarum Bohemoslovaca 2001;50:537-46
16. Leiter EH. Differential susceptibility of BALB/c sublines to diabetes induction by multi-dose streptozotocin treatment. Curr Top Microbiol Immunol 1985;122:78-85
17. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008;51:216-26
18. Wang Z, Gleichmann H. GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 1998;47:50-6
19. Imaeda A, Kaneko T, Aoki T, Kondo Y, Nagase H. DNA damage and the effect of antioxidants in streptozotocin-treated mice. Food Chem Toxicol 2002;40:979-87
20. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol 2006;290:F214-22
21. Hayashi K, Kojima R, Ito M. Strain differences in the diabetogenic activity of streptozotocin in mice. Biol Pharmaceut Bull 2006;29:1110-19
22. Bell RC, Khurana M, Ryan EA, Finegood DT. Gender differences in the metabolic response to graded numbers of transplanted islets of Langerhans. Endocrinology 1994;135:2681-7
23. Cortright RN, Collins HL, Chandler MP, Lemon PW, DiCarlo SE. Diabetes reduces growth and body composition more in male than in female rats. Physiol Behav 1996;60:1233-8
24. Le May C, Chu K, Hu M, et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 2006;103:9232-7
25. Leiter EH. Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proc Nat Acad Sci USA 1982;79:630-4
26. Candela S, Hernandez RE, Gagliardino JJ. Circadian variation of the streptozotocin-diabetogenic effect in mice. Experientia 1979;35:1256-7
27. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton, Vic) 2007;12:261-6
28. Lu WT, Juang JH, Hsu BR, Huang HS. Effects of high or low dose of streptozocin on pancreatic islets in C57BL/6 and C.B17-SCID mice. Transplant Proc 1998;30:609-10
29. Merino JF, Nacher V, Raurell M, Aranda O, Soler J, Montanya E. Improved outcome of islet transplantation in insulin-treated diabetic mice: effects on beta-cell mass and function. Diabetologia 1997;40:1004-10
30. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 1996;178:176-81
31. Grossman EJ, Lee DD, Tao J, et al. Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PloS One 2010;5:e8749
32. Weide LG, Lacy PE. Low-dose streptozocin-induced autoimmune diabetes in islet transplantation model. Diabetes 1991;40:1157-62
33. Cossel L, Schneider E, Kuttler B, et al. Low dose streptozotocin induced diabetes in mice. Metabolic, light microscopical, histochemical, immunofluorescence microscopical, electron microscopical and morphometrical findings. Exp Clin Endocrinol 1985;85:7-26
34. Asplund K, Grankvist K, Marklund S, Taljedal IB. Partial protection against streptozotocin-induced hyperglycaemia by superoxide dismutase linked to polyethylene glycol. Acta Endocrinol 1984;107:390-4
35. Negishi M, Shimizu H, Ohtani K, Mori M. Acarbose partially prevents the development of diabetes mellitus by multiple low-dose streptozotocin administration. Diabetes Res Clin Pract 1996;33:15-19
36. Ito M, Kondo Y, Nakatani A, Naruse A. New model of progressive non-insulin-dependent diabetes mellitus in mice induced by streptozotocin. Biol Pharmaceut Bull 1999;22:988-9
37. Dekel Y, Glucksam Y, Elron-Gross I, Margalit R. Insights into modeling streptozotocin-induced diabetes in ICR mice. Lab Anim 2009;38:55-60
38. Axler DA. Stability of the diabetogenic activity of streptozotocin. IRCS Med Sci 1982;10:157-8
39. Iwakiri R, Nagafuchi S, Kounoue E, et al. Immunohistochemical study of insulitis induced by multiple low doses of streptozocin in CD-1 mice. Diabetes Res Clin Pract 1990;9:75-82
40. Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF Jr. Studies of streptozotocin-induced insulitis and diabetes. Proc Nat Acad Sci USA 1977;74:2485-9
41. Mosci P, Vecchiarelli A, Cenci E, Puliti M, Bistoni F. Low-dose streptozotocin-induced diabetes in mice. I. Course of Candida albicans infection. Cell Immunol 1993;150:27-35
42. Reddy S, Wu D, Elliott RB. Low dose streptozotocin causes diabetes in severe combined immunodeficient (SCID) mice without immune cell infiltration of the pancreatic islets. Autoimmunity 1995;20:83-92
43. Molina PE. Endocrine Physiology. 2nd edn. New York: Lange Medical Books/McGraw-Hill, 2006
44. Gerling IC, Friedman H, Greiner DL, Shultz LD, Leiter EH. Multiple low-dose streptozocin-induced diabetes in NOD-scid/scid mice in the absence of functional lymphocytes. Diabetes 1994;43:433-40
45. Xie X, Li S, Liu S, Lu Y, Shen P, Ji J. Proteomic analysis of mouse islets after multiple low-dose streptozotocin injection. Biochim Biophys Acta 2008;1784:276-84
46. Ninova D, Dean PG, Deeds M, Stegall MD. A novel model of allograft rejection: immune reconstitution of Rag-1 recipients with 2C transgenic T-cell receptor lymphocytes. Transpl Int 2005;18:101-10
47. Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris DC. Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int 2005;68:391-8
48. Junod A, Lambert AE, Orci L, Pictet R, Gonet AE, Renold AE. Studies of the diabetogenic action of streptozotocin. Proc Soc Exp Biol Med 1967;126:201-5
49. Donovan J, Brown P. Parenteral injections. Curr Protoc Neurosci 2005; Appendix 4:Appendix 4F
50. Evan AP, Mong SA, Gattone VH, Connors BA, Aronoff GR, Luft FC. The effect of streptozotocin and streptozotocin-induced diabetes on the kidney. Renal Physiol 1984;7:78-89
51. Junod A, Lambert AE, Stauffacher W, Renold AE. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 1969;48:2129-39
52. Bloch K, Vorobeychik M, Yavrians K, Azarov D, Bloch O, Vardi P. Improved activity of streptozotocin-selected insulinoma cells following microencapsulation and transplantation into diabetic mice. Cell Biol Int 2006;30:138-43
53. Kume E, Fujimura H, Matsuki N, et al. Hepatic changes in the acute phase of streptozotocin (SZ)-induced diabetes in mice. Exp Toxicol Pathol 2004;55:467-80
54. Kim HI, Yu JE, Park CG, Kim SJ. Comparison of four pancreatic islet implantation sites. J Korean Med Sci 2010;25:203-10